You might have come across mentions of BPC-157 from influencers or online forums touting its benefits
DOI: 10.1016/j.arth.2021.04.017 [Google Scholar] Bliddal H, Bays H, Czernichow S, Udden Hemmingsson J, Hjelmesaeth J, Hoffmann Morville T, et al
The views expressed are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health
Duration of benefit also differs: phentermine effects diminish after stopping, whereas GLP-1 weight loss persists longer when maintained
Right now, Medicare plans are allowed to cover weight-loss drugs for "nonobesity uses," like reducing the risk of heart attacks
Understanding these risks is essential for both healthcare professionals and patients